Mirdametinib(Ezmekly)

Mirdametinib is a prescription drug targeting MEK1 and MEK2, and it must be used strictly in accordance with doctors' instructions.

Targets of Action

MEK1, MEK2

Dosage and Administration

Route and frequency of administration of Mirdametinib: Oral, twice daily.

The dosage of Mirdametinib should be adjusted according to the patient's actual condition. Please consult your physician for specific instructions and follow medical advice.

Recommended reading: Dosage and Administration of Mirdametinib

Side Effects

Common side effects: Diarrhea, nausea, muscle, joint, and bone pain, etc.

Serious side effects: Eye problems, blurred vision, vision loss, etc.

Use in Special Populations

Pregnancy: Before you start treatment with Mirdametinib, your healthcare provider should check whether you are pregnant. During treatment with Mirdametinib and for 6 weeks after the last dose, please take effective contraceptive measures.

Breastfeeding: It is not known whether Mirdametinib passes into breast milk. Do not breastfeed during treatment with Mirdametinib and for 1 week after the last dose.

Daily Precautions

1. Inform patients and caregivers that Mirdametinib may cause serious ocular adverse reactions; if any vision changes occur, contact a healthcare provider immediately.

2. Inform patients and caregivers that Mirdametinib may cause a decrease in left ventricular ejection fraction (LVEF); if any signs or symptoms of left ventricular dysfunction occur, notify a healthcare provider immediately.

3. Inform patients and caregivers that Mirdametinib can cause severe skin adverse reactions; if skin discomfort occurs, contact a healthcare provider promptly; additionally, this medication may cause hair loss.

FDA，2025.11